E2F and cell cycle control: A double-edged sword

Archives of Biochemistry and Biophysics

Volumn 412, Issue 2, 2003, Pages 157-169

  Stevens, Craig ^a   La Thangue, Nicholas B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATM PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; DIHYDROFOLATE REDUCTASE; DNA DIRECTED DNA POLYMERASE ALPHA; HISTONE DEACETYLASE; MINICHROMOSOME MAINTENANCE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN MDM2; PROTEIN P107; PROTEIN P130; PROTEIN P300; PROTEIN P73; RETINOBLASTOMA PROTEIN; SMAD3 PROTEIN; THYMIDINE KINASE; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR E2F5; TRANSCRIPTION FACTOR E2F6; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BINDING SITE; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 0037445901     PISSN: 00039861     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9861(03)00054-7     Document Type: Short Survey

References (129)

1. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
2. Nevins J.R. E2F: a link between the Rb tumour suppressor protein and viral oncoproteins. Science. 258:1992;424-429.
3. La Thangue N.B., Rigby P.W. An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell. 49:1987;507-513.
4. Dyson N. The regulation of E2F by pRb-family proteins. Genes Dev. 12:1998;2245-2262.
5. ARF links the tumour suppressor RB and p53 Nature. 395:1998;124-125.
6. Irwin M., Martin M.C., Phillips A.C., Seelan R.S., Smith D.I., Liu W., Flores E.R., Tsai K.Y., Jacks T., Vousden K.H., Kaelin W.G. Jr. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 407:2000;645-648.
7. Lissy N.A., Davis P.K., Irwin M., Kaelin W.G., Dowdy S.F. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature. 407:2000;642-644.
8. Moroni M.C., Hickman E.S., Denchi E.L., Caprara G., Colli E., Cecconi F., Müller H., Helin K. Apaf-1 is a transcriptional target for E2F and p53. Nature Cell Biol. 3:2001;552-558.
9. Bandara L.R., La Thangue N.B. Adenovirus E1A prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature. 351:1991;494-497.
10. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
11. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., Drija T.P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:1986;643-646.
12. Wang J.Y. Retinoblastoma protein in growth suppression and death protection. Curr. Opin. Genet. Dev. 7:1997;39-45.
13. Mulligan G., Jacks T. The retinoblastoma gene family: cousins with overlapping interests. Trends Genet. 14:1998;223-229.
14. Clarke A.R., Maandag E.R., Van Roon M., Van der Luft N.M.T., Van der Valk M., Hooper M.L., Berns A., Te Riele H. Requirement for a functional Rb-1 gene in murine development. Nature. 359:1992;328-330.
15. Cobrinik D., Lee M.H., Hannon G., Mulligan G., Bronson R.T., Dyson N., Harlow E., Beach D., Weinberg R.A., Jacks T. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev. 10:1996;1633-1644.
16. Lee M.H., Williams B.O., Mulligan G., Mukai S., Bronson R.T., Dyson N., Harlow E., Jacks T. Targeted disruption of p107, functional overlap between p107 and Rb genes. Genes Dev. 10:1996;1621-1632.
17. Mittnacht S. Control of pRb phosphorylation. Curr. Opin. Genet. Dev. 8:1998;21-27.
18. Ohtani K., DeGregori J., Nevins J.R. Regulation of the cyclin E gene by the transcription factor E2F1. Proc. Natl. Acad. Sci. USA. 92:1995;12146-12150.
19. Botz J., Zerfass-Thome K., Spitkovsky D., Delius H., Vogt B., Eilers M., Hatziegeorgiou A., Jansen-Dürr P. Cell cycle regulation of the murine cyclinE gene depends on an E2F binding site in the promoter. Mol. Cell. Biol. 16:1996;3401-3409.
20. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18:1998;753-761.
21. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
22. de la Luna S., Burden M.J., Lee C.-W., La Thangue N.B. Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal. J. Cell. Sci. 109:1996;2443-2452.
23. Adams M.R., Sears R., Nuckolls F., Leone G., Nevins J.R. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol. Cell. Biol. 20:2000;3633-3639.
24. Lees J.A., Saito M., Vidal M., Valentine M., Look T., Harlow E., Dyson N., Helin K. The retinoblastoma protein binds to a family of E2F transcription factors. Mol. Cell. Biol. 13:1993;7813-7825.
25. Buck V., Allen K.E., Sørensen T.S., Bybee A., Hijmans E.M., Voorhoeve P.M., Bernards R., La Thangue N.B. Molecular and functional characterisation of E2F-5, a new member of the E2F family. Oncogene. 11:1995;31-38.
26. Zhang Y., Chellappan S.P. Cloning and characterisation of human DP2, a novel dimerisation partner of E2F. Oncogene. 10:1995;2085-2093.
27. Tao Y., Kassatly R.F., Cress D.W., Horowitz J.M. Subunit composition determines E2F DNA-binding site specificity. Mol. Cell. Biol. 17:1997;6994-7007.
28. Gaubatz S., Lees J.A., Lindeman G.J., Libingston D.M. E2F-4 is exported from the nucleus in a CRM1-dependent manner. Mol. Cell. Biol. 21:2001;1384-1392.
29. Morkel M., Wenkel J., Bannister A.J., Kouzarides T., Hagemeier C. An E2F-like repressor of transcription. Nature. 390:1997;567-568.
30. DeGregori J., Leone G., Miron A., Jakoi L., Nevins J.R. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA. 94:1997;7245-7250.
31. Johnson D.G., Schwarz J.K., Cress W.D., Nevins J.R. Expression of transcription factor E2F-1 induces quiescent cells to enter S phase. Nature. 365:1993;349-352.
32. Asano M., Nevins J.R., Wharton R.P. Ectopic E2F expression induces S phase and apoptosis in Drosophila imaginal discs. Genes Dev. 10:1996;1422-1432.
33. Lukas J., Petersen B.O., Holm K., Bartek J., Helin K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4a mediated growth suppression. Mol. Cell. Biol. 16:1996;1047-1057.
34. Wang Z.M., Yang H., Livingston D.M. Endogenous E2F-1 promotes timely G0 exit of resting mouse embryo fibroblasts. Proc. Natl. Acad. Sci. USA. 95:1998;15583-15586.
35. Wu C.-L., Classon M., Dyson N., Harlow E. Expression of dominant-negative mutant DP-1 blocks cell cycle progression in G1. Mol. Cell. Biol. 16:1996;3698-3706.
36. Wu L., Timmers C., Maiti B., Saavedra H.I., Sang L., Chong G.T., Nuckolls F., Giangrande P., Wright F.A., Field S.J., Greenberg M.E., Orkin S., Nevins J.R., Robinson M.L., Leone G. The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 414:2001;457-462.
37. DeGregori J., Leone G., Ohtani K., Miron A., Nevins J.R. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9:1995;2873-2887.
38. Schwarz J.K., Bassing C.H., Kovesdi I., Datto M.B., Blazing M., George S., Wang X., Nevins J.R. Expression of the E2F-1 transcription factor overcomes TGF-β mediated growth suppression. Proc. Natl. Acad. Sci. USA. 92:1995;483-487.
39. Mann D.J., Jones N.C. E2F-1 but not E2F-4 can overcome p16-induced G1 cell cycle arrest. Curr. Biol. 6:1996;474-483.
40. Qin X.-Q., Livingston D.M., Kaelin W.G. Jr., Adams P.D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 91:1994;10918-10922.
41. Ross J.F., Lui X., Dynlacht B.D. Mechanism of transcriptional repression of E2F by the retinoblastoma tumour suppressor protein. Mol. Cell. 3:1999;195-205.
42. Zhang H., Postigo A.A., Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFβ, and contact inhibition. Cell. 97:1999;53-61.
43. Ross J.F., Naar A., Cam H., Gregory R., Dynlacht B.D. Active repression and E2F inhibition by pRb are biochemically distinguishable. Genes Dev. 15:2001;392-397.
44. Brehm A., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 391:1998;597-601.
45. Luo R.X., Postigo A.A., Dean D.C. Rb interacts with histone deacetylase to repress transcription. Cell. 92:1998;463-473.
46. Magnaghi-Jaulin L., Groisman R., Naguibneva I., Robin P., Lorain S., Le Villain J.P., Troalen F., Trouche D., Harel-Bellan A. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 391:1998;601-605.
47. Nielsen S.J., Schneider R., Bauer U.-M., Bannister A.J., Morrison A., O'Carroll D., Firestein R., Cleary M., Jenuwein T., Herrera R.E., Kouzarides T. Rb targets histone H3 methylation and HP1 to promoters. Nature. 412:2001;561-565.
48. Zhang H., Gavin M., Dahiya A., Postigo A.A., Ma D., Luo R.X., Harbour J.W., Dean D.C. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell. 101:2000;78-89.
49. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14:2000;2393-2409.
50. Bannister A.J., Zegerman P., Partridge J.F., Miska E.A., Thomas J.O., Allshire R.C., Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 410:2001;120-124.
51. Lachner M., O'Carroll D., Rea S., Mechtler K., Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature. 410:2001;116-120.
52. Jenuwein T., Allis D. Translating the histone code. Science. 293:2001;1074-1080.
53. Beijersbergen R.L., Kerkhoven R.M., Zhu L., Carlee L., Voorhoeve P.M., Bernards R. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev. 8:1994;2680-2690.
54. Hijmans E.M., Voorhoeve P.M., Beijersbergen R.L., van't Veer L.J., Bernards R. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol. Cell. Biol. 15:1995;3082-3089.
55. Allen K.E., de la Luna S., Kerkhoven R.M., Bernards R., La Thangue N.B. Distinct mechanisms of nuclear accumulation regulate the functional consequence of E2F transcription factors. J. Cell Biol. 110:1997;2810-2831.
56. Muller H., Moroni M.C., Vigo E., Petersen B.O., Bartek J., Helin K. Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol. Cell. Biol. 17:1997;5508-5520.
57. Verona R., Moberg K., Estes S., Starz M., Vernon J.P., Lees J.A. E2F activity is regulated by cell-cycle-dependent changes in subcellular localization. Mol. Cell. Biol. 17:1997;7268-7282.
58. Magae J., We C., Illenye S., Harlow E., Heintz N.H. Nuclear localisation of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J. Cell. Sci. 109:1996;1717-1726.
59. Lindeman G.L., Gaubatz S., Livingston D.M., Ginsberg D. The subcellular localisation of E2F-4 is cell-cycle dependent. Proc. Natl. Acad. Sci. USA. 94:1997;5095-5100.
60. Morberg K., Starz M.A., Lees J.A. E2F-4 switches from p130 to p107 and pRb in response to cell cycle re-entry. Mol. Cell. Biol. 12:1996;232-239.
61. Dalton S. Cell cycle regulation of the human CDC2 gene. EMBO J. 11:1992;1797-1804.
62. Lam E.W., Watson R.J. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J. 12:1993;2705-2713.
63. Hsiao K.M., McMahon S.L., Farnham P.J. Multiple DNA elements are required for the growth regulation of the mouse E2F-1 promoter. Genes Dev. 8:1994;1526-1537.
64. Takahashi Y., Rayman J.B., Dynlacht B.D. Analysis of promoter binding by the E2F and pRb families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev. 14:2000;804-816.
65. Tommasi S., Pfeifer G.P. In vivo structure of the human cdc2 promoter: release of a p130-E2F4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Mol. Cell. Biol. 15:1995;6901-6913.
66. Huet X., Rech J., Plet A., Vie A., Blanchard J.M. Cyclin A expression is under negative transcriptional control during the cell cycle. Mol. Cell. Biol. 16:1996;3789-3798.
67. Zwicker J., Liu N., Engeland K., Lucibello F.C., Muller R. Cell cycle regulation of E2F site occupation in vivo. Science. 271:1996;1595-1597.
68. Morris L., Allen K.E., La Thangue N.B. Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators. Nat. Cell Biol. 2:2000;232-239.
69. Chen C., Kang Y., Siegel P.M., Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell. 110:2002;19-32.
70. Trimarchi J.M., Fairchild B., Wen J., Lees J.A. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc. Natl. Acad. Sci. USA. 98:2001;1519-1524.
71. Ogawa H., Ishiguro K., Gaubatz S., Livingston D., Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in Go cells. Science. 296:2002;1132-1136.
72. Breiling A., Turner B.M., Bianchi M.E., Orlando V. General transcription factors bind promoters repressed by Polycomb group proteins. Nature. 412:2001;651-655.
73. Krek W., Ewen M.E., Shirodkar S., Arany Z., Kaelin W.G., Livingston D.M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclinA-dependent protein kinase. Cell. 78:1994;161-172.
74. Xu M., Sheppard K.A., Peng C.Y., Yee A.S., Piwnica-Worms H Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol. 14:1994;8420-8431.
75. Krek W, Xu G., Livingston D.M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 83:1995;1149-1158.
76. Elledge S.J., Harper J.W. The role of protein stability in the cell cycle and cancer. Biochem. Biophys. Acta. 1377:1998;M61-M70.
77. Hateboer G., Kerkhoven R.M., Shvarts A., Bernards R., Beijerbergen R.L. Deregulation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 10:1996;2960-2970.
78. Hofmann F., Martelli F., Livingston D.M., Wang Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10:1996;2949-2959.
79. SKP2 and E2F-1 underlies the regulation of E2F-1 degradation Nat. Cell Biol. 1:1999;14-19.
80. Loughran O., La Thangue N.B. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol. Cell. Biol. 20:2000;2186-2197.
81. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase for tumour suppressor p53. FEBS Lett. 420:1997;25-27.
82. ARF targets certain E2F species for degradation Proc. Natl. Acad. Sci. USA. 98:2001;4455-4460.
83. ARF regulates E2F activity Oncogene. 21:2002;4220-4230.
84. Trouche D., Cook A., Kouzarides T. The CBP co-activator stimulates E2F1/DP1 activity. Nucleic Acids Res. 24:1996;4139-4145.
85. Chan H.M., La Thangue N.B. P300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell. Sci. 114:2001;2363-2373.
86. Martinez-Balbás M.A., Bauer U.-M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F-1 activity by acetylation. EMBO J. 19:2000;662-671.
87. Chan H.M., Krstic-Demonacos M., Smith L., Demonacos C., La Thangue N.B. Acetylation control of the retinoblastoma tumour suppressor protein. Nat. Cell Biol. 3:2001;667-674.
88. Eckner R., Ewen M.E., Newsome D., Gerdes M., DeCaprio J.A., Lawrence J.B., Livingston D.M. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8:1994;869-884.
89. Field S.J., Tsai F.Y., Kuo F., Zubiaga A.M., Kaelin W.G. Jr., Livingston D.M., Orkin S.H., Greenberg M.E. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 85:1996;549-561.
90. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N. Tumour induction and tissue atrophy in mice lacking E2F-1. Cell. 85:1996;537-547.
91. Humbert P.O., Verona R., Trimarchi J.M., Rogers C., Dandapani S., Lees J.A. E2F3 is critical for normal cellular proliferation. Genes Dev. 14:2000;690-703.
92. Leone G., Degregori J., Yan Z., Jakoi L., Ishida S., Williams R.S., Nevins J.R. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev. 12:1998;2120-2130.
93. Humbert P.O., Rogers C., Ganiatsas S., Landsberg R.L., Trimarchi J.M., Dandapani S., Brugnara C., Erdman S., Schrenzel M., Bronson R.T., Lees J.A. E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol. Cell. 6:2000;281-291.
94. Rempel R.E., Saenz-Robles M.T., Storms R., Morham S., Ishida S., Engel A., Jakoi L., Melhem M.F., Pipas J.M., Smith C., Nevins J.R. Loss of E2F4 activity leads to abnormal development of multiple cellular lineages. Mol. Cell. 6:2000;293-306.
95. Lindeman G.J., Dagnino l., Gaubatz S., Xu Y., Bronson R.T., Warren H.B., Livingston D.M. A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targetting. Genes Dev. 12:1998;1092-1098.
96. Bruce J.L., Hurford R.K. Jr., Classon M., Koh J., Dyson N. Requirements for cell cycle arrest by p16INK4a. Mol. Cell. 6:2000;737-742.
97. Gaubatz S., Lindeman G.J., Ishida S., Jakoi L., Nevins J.R., Livingston D.M., Rempel R.E. E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol. Cell. 6:2000;729-735.
98. Hurford R.K., Cobrinik D., Lee M.H., Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev. 11:1997;1447-1463.
99. Lukas C., Sorensen C.S., Kramer E., Santoni-Rugiu E., Lindeneg C., Peters J., Bartek J., Lukas J. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature. 401:1999;815-818.
100. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases and cdk inhibitors in human cancer. Adv. Cancer Res. 68:1996;67-108.
101. Welcker M., Lukas J., Strauss M., Bartek J. Enhanced protein stability: a novel mechanism of D-type cyclin overabundance identified in human sarcoma cells. Oncogene. 13:1996;419-425.
102. Koh J., Enders G.H., Dynlacht B.D., Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 375:1995;506-510.
103. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Buschenfelde K.H., Beach D. A p16 INK4a insensitive cdk4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1995;1281-1284.
104. Yamasaki L. Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Biochem. Biopohys. Acta. 1423:1999;M9-M15.
105. Pierce A.M., Schneider-Broussard R., Gimenez-Conti I.B., Russel J.L., Conti C.J., Johnson D.G. E2F-1 has both oncogenic and tumour-suppressive properties in transgenic model. Mol. Cell. Biol. 19:1999;6408-6414.
106. Johnson D.G., Douglas Cress W., Jakoi L., Nevins J.R. Oncogenic capacity of the E2F-1 gene. Proc. Natl. Acad. Sci. USA. 91:1994;12823-12827.
107. +/- mice Nat. Genet. 18:1998;360-364.
108. Hsieh J.K., Fredersdorf S., Kouzarides T., Martin K., Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11:1997;1840-1852.
109. Phillips A.C., Bates S., Ryan K.M., Helin K., Vousden K.H. Induction of DNA synthesis and apoptosis are separable functions of E2F1. Genes Dev. 11:1997;1853-1863.
110. Phillips A.C., Ernst M.K., Bates S., Rice N.R., Vousden K.H. E2F1 potentiates cell death by blocking anti-apoptotic signalling pathways. Mol. Cell. 4:1999;771-781.
111. ARF is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo Mol. Cell. Biol. 22:2002;370-377.
112. Blattner C., Sparks A., Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 19:1999;3704-3713.
113. Lin W.C., Lin F.T., Nevins J.R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 15:2001;1833-1844.
114. C. Stevens, L. Smith, N.B. La Thangue, Checkpoint kinase activates E2F-1 in response to DNA damage, 2002 (in press).
115. Canman C.E., Lim D., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
116. Hirao A., Kong Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:2000;1824-1827.
117. Maser R.S., Mirzoeva O.K., Wells J., Olivares H., Williams B.R., Zinkel R.A., Farnham P.J., Petrini J.H. Mre11 complex and DNA replication: Linkage of E2F and sites of DNA synthesis. Mol. Cell. Biol. 21:2001;6006-6016.
118. Bosco G., Du W., Orr-Weaver T.L. DNA replication control through interaction of E2F-RB and the origin recognition complex. Nat. Cell Biol. 3:2001;289-295.
119. Porse B.T., Pedersen T.Å., Xiufeng X., Lindberg B., Wewer U.M., Friis-Hansen L., Nerlov C. E2F repression by C/EBP is required for adipogenesis and granulopoiesis in vivo. Cell. 107:2001;247-258.
120. Wang J., Helin K., Jin P., Nadal-Ginard B. Inhibition of in vitro myogenic differentiation by cellular transcription factor E2F-1. Cell Growth Differ. 6:1995;1299-1306.
121. Dicker A.J., Popa C., Dahler A.L., Serewko M.M., Hilditch-Maguire P.A., Frazer I.H., Saunders N.A. E2F-1 induces proliferation-specific genes and suppresses squamous differentiation-specific genes in human epidermal keratinocytes. Oncogene. 19:2000;2887-2894.
122. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., Weinberg R.A. Effects of an Rb mutation in the mouse. Nature. 359:1992;295-300.
123. Lee E.Y., Chang C.Y., Hu N., Wang Y.C., Lai C.C., Herrup K., Lee W.H., Bradley A. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature. 359:1992;288-294.
124. Slomiany B.A., D'Arigo K.L., Kelly M.M., Kurtz D.T. C/EBPα inhibits cell growth via direct repression of E2F-DP-mediated transcription. Mol. Cell. Biol. 20:2000;5986-5997.
125. Johansen L.M., Iwama I., Lodie T.A., Sasaki K., Felsher D.W., Golub T.R., Tenen D.G. c-Myc is a critical target for C/EBP in granulopoiesis. Mol. Cell. Biol. 21:2001;3789-3806.
126. Bergh G., Ehinger M., Olsson I., Jacobsen S.E., Gullberg U. Involvement of the retinoblastoma protein in monocytic and neutrophilic lineage commitment of human bone marrow progenitor cells. Blood. 94:1999;1971-1978.
127. Mori A., Higashi H., Hoshikawa Y., Imamura M., Asaka M., Hatakeyama M. Granulocytic differentiation of myeloid progenitor cells by p130, the retinoblastoma tumour suppressor homologue. Oncogene. 18:1999;6209-6221.
128. Fajas L., Landsberg L., Huss-Garcia Y., Sardet C., Lees J.A., Auwerx J. E2Fs regulate adipocyte differentiation. Dev. Cell. 3:2002;39-49.
129. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., Dynlacht B.D. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev. 16:2002;245-256.